Tools
It ain't me, babe.
Lake Union Confusion
When Lake Union residents and local businesses lost another Seattle landmark, Denny's, a few weeks ago, they blamed the only person they could--Paul Allen. "He's been buying everything around here," says Missy Welch, manager at West Marine Products, a boating company off Mercer Street.
Because Allen and his company, Vulcan Northwest, have been buying up a ton of Lake Union property lately (44 acres so far), the Allen guess seemed logical. However, according to the King County Department of Assessments and Vulcan Northwest, the Denny's property is not owned by Allen.
Stranger Personals
The current property, now valued at over $1 million, is owned by Tosco, a Connecticut- based oil company. PAT KEARNEY
Twilight Rezone
In a parade of 6-3 votes (Nick Licata, Judy Nicastro, and Peter Steinbrueck being the only three who get it), the deluded Seattle City Council passed rezone plans for the string of neighborhoods along Sound Transit's "light-rail line." Unfortunately, the majority of those neighborhoods aren't on the light-rail route, because the once-mighty 21-mile line has been reduced to an irrelevant eight miles. In other words, the light-rail line that voters approved in 1996--at least $1.1 billion over budget now--is imaginary.
Evidently, council members like Richard Conlin are happy living in that imaginary land. "These rezones are predicated on the idea that a mass-transportation system would serve [the neighborhoods]," Conlin said prior to his yea vote, apparently unaware that Sound Transit's loopy plan isn't going to serve most of the neighborhoods he voted to rezone.
It's not clear if Conlin understood the irony of his comments. Let's repeat them back to him and see if he gets it: "These rezones are predicated on the idea that a mass-transportation system would serve [the neighborhoods]."
Conlin is undeterred. "We have to get a transportation system that serves those places that we've agreed upon for the past 10 years," he says. JOSH FEIT
New Genes
ZymoGenetics, a Seattle-based biotechnology company, could be starting clinical trials of its gene-splicing drugs as early as next year, according to a July 27 Puget Sound Business Journal article. With the trials, ZymoGenetics is directly trying to enter the most profitable industry in America--the pharmaceutical market. (ZymoGenetics was previously just a gene-research business that licensed its discoveries.)
If the trials are successful, ZymoGenetics says humans can expect rapid wound-healing drugs like its human recombinant Factor 13 and human recombinant thrombin by 2003. PAT KEARNEY
RSS
Facebook
Twitter
Comments (0)